Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated contest for the biotech firm. The deal, finalized after Novo Nordisk withdrew ...
Pfizer is a Buy for medium- to long-term investors, trading at a low P/E and undervalued versus peers, with strong non-COVID growth. Strategic pivots include aggressive R&D, cost-cutting, and the ...
WASHINGTON, DC - SEPTEMBER 30: Pfizer CEO Albert Bourla speaks shakes hands with U.S. President Donald Trump as Centers for Medicare & Medicaid Services Mehmet Oz looks on after Trump announced a deal ...
Novo Nordisk’s CEO dared Pfizer to bid more if it wanted obesity drug developer Metsera so badly. So Pfizer did, with a $10 billion bid that edges out what the Danish pharmaceutical giant was willing ...
The drugmaker reported revenue that fell from a year ago amid slumping sales of COVID vaccines and treatments, but still topped expectations Pfizer's buyout bid for Metsera was deemed inferior to the ...
Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...
The Trump administration and Pfizer PFE announced an agreement on Sept. 30 that includes most-favored-nation pricing for Pfizer’s drugs in Medicaid programs, discounts for direct sales of Pfizer drugs ...
After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results